Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors. A new drug class for the treatment of hypercholesterolemia

被引：1
|
作者：
Martinez de Victoria, Emilio Ortega [1 ,2 ]
机构：
[1] Univ Barcelona, IDIBAPS, Hosp Clin Barcelona, Serv Endocrinol & Nutr, Barcelona, Spain
[2] ISCIII, CIBER Fisiopatol Obesidad & Nutr CIBEROBN, Madrid, Spain
来源：
ENDOCRINOLOGIA DIABETES Y NUTRICION | 2017年 / 64卷 / 07期
关键词：
DENSITY-LIPOPROTEIN CHOLESTEROL; CORONARY-HEART-DISEASE; FAMILIAL HYPERCHOLESTEROLEMIA; CARDIOVASCULAR EVENTS; RISK; DISCONTINUATION; METAANALYSIS; ALIROCUMAB; RATIONALE; STATINS;
D O I：
10.1016/j.endinu.2017.04.005
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：341 / 344
页数：4
相关论文
共 50 条
  • [21] Role of proprotein convertase subtilisin/kexin type 9 (PCSK9) in diabetic complications
    Imaralu, Omonzejie E.
    Narasimhulu, Chandrakala Aluganti
    Singal, Pawan K.
    Singla, Dinender K.
    CANADIAN JOURNAL OF PHYSIOLOGY AND PHARMACOLOGY, 2024, 102 (01) : 14 - 25
  • [22] Molecular and cellular function of the proprotein convertase subtilisin/kexin type 9 (PCSK9)
    Rainer Schulz
    Klaus-Dieter Schlüter
    Ulrich Laufs
    Basic Research in Cardiology, 2015, 110
  • [23] Inhibition of proprotein convertase subtilisin/kexin type 9 (PCSK9): A new approach in lipid lowering treatment
    Klouras, E.
    Liberopoulos, E.
    Elisaf, M.
    ARCHIVES OF HELLENIC MEDICINE, 2015, 32 (01): : 77 - 84
  • [24] Molecular and cellular function of the proprotein convertase subtilisin/kexin type 9 (PCSK9)
    Schulz, Rainer
    Schlueter, Klaus-Dieter
    Laufs, Ulrich
    BASIC RESEARCH IN CARDIOLOGY, 2015, 110 (02)
  • [25] Proprotein convertase subtilisin/kexin type 9 (PCSK9) in the central nervous system
    Bell, Andrew S.
    Wagner, Josephin
    Rosoff, Daniel B.
    Lohoff, Falk W.
    NEUROSCIENCE AND BIOBEHAVIORAL REVIEWS, 2023, 149
  • [26] Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors for Treatment of High Cholesterol Levels Effectiveness and Value
    Tice, Jeffrey A.
    Kazi, Dhruv S.
    Pearson, Steven D.
    JAMA INTERNAL MEDICINE, 2016, 176 (01) : 107 - 108
  • [27] Proprotein convertase subtilisin kexin 9 (PCSK9) inhibitors: a district general hospitals experience
    Whicher, C. A.
    Tjerkstra, E.
    Waise, A.
    DIABETIC MEDICINE, 2017, 34 : 155 - 155
  • [28] Discovery and Early Development of Small Molecule Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors
    Piotrowski D.W.
    McInturff E.L.
    ACS Symposium Series, 2019, 1332 : 267 - 296
  • [29] Neurological Effects of Proprotein Convertase Subtilisin/kexin Type 9(PCSK9) Inhibitors: Direct and Indirect Comparisons
    Patel, Nirav
    Kalra, Rajat
    Venkatraman, Anand
    Godara, Hemant
    Arora, Garima
    Bajaj, NavKaranbir S.
    Arora, Pankaj
    CIRCULATION, 2016, 134
  • [30] The impact of discontinuing proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors on clinical outcomes
    Tsubata, H.
    Wakana, N.
    Yanishi, K.
    Nakanishi, N.
    Zen, K.
    Nakamura, T.
    Matoba, S.
    EUROPEAN HEART JOURNAL, 2024, 45
12345